Glycogen storage disease type VII
Última atualização 26 Jul 2023
Atende aos diretrizes editoriais
- BaixarBaixar
- Compartilhar
- Language
- Discussão
- Ask Patient
- Versão em Áudio
- Adicionar às fontes preferidas no Google
Glycogen storage disease type VII (GSDVII) is an inherited disorder caused by an inability to break down a complex sugar called glycogen in muscle cells. A lack of glycogen breakdown interferes with the function of muscle cells.
Escolhas de vídeos para Condições genéticasBiblioteca de vídeos
Descrição
Glycogen storage disease type VII (GSDVII) is an inherited disorder caused by an inability to break down a complex sugar called glycogen in muscle cells. A lack of glycogen breakdown interferes with the function of muscle cells.
There are four types of GSDVII. They are differentiated by their signs and symptoms and the age at which symptoms first appear.
The classical form of GSDVII is the most common form. Its features usually appear in childhood. This form is characterised by muscle pain and cramps, often following moderate exercise; strenuous exercise can lead to nausea and vomiting. During exercise, muscle tissue can be abnormally broken down, releasing a protein called myoglobin. This protein is processed by the kidneys and released in the urine (myoglobinuria). If untreated, myoglobinuria can damage the kidneys and lead to kidney failure. Some people with the classical form of GSDVII develop high levels of a waste product called uric acid in the blood (hyperuricemia) because the damaged kidneys are unable to remove uric acid effectively. Affected individuals may also have elevated levels of a molecule called bilirubin in the blood that can cause yellowing of the skin and whites of the eyes (jaundice). Individuals with classical GSDVII often have elevated levels of an enzyme called creatine kinase in their blood. This finding is a common indicator of muscle disease.
Infants with the severe infantile form of GSDVII have low muscle tone (hypotonia) at birth, which leads to muscle weakness (myopathy) that worsens over time. Affected infants have a weakened and enlarged heart (cardiomyopathy) and difficulty breathing normally. Individuals with this form of GSDVII usually do not survive past their first year of life.
In the late-onset form of GSDVII, myopathy is typically the only feature. The muscle weakness appears in adulthood, although some individuals have difficulty with sustained exercise starting in childhood. The weakness generally affects the muscles closest to the center of the body (proximal muscles).
The hemolytic form of GSDVII is characterised by hemolytic anaemia, in which red blood cells are broken down (undergo hemolysis) prematurely, causing a shortage of red blood cells (anaemia). People with the hemolytic form of GSDVII do not experience any signs or symptoms of muscle pain or weakness related to the disorder.
Padrões de herança
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
Glycogenosis 7
GSD VII
GSD7
Muscle phosphofructokinase deficiency
PFKM deficiency
Deficiência de fosfofrutoquinase
Tarui disease
Related patient information and medicines

Patient information leaflet
Distúrbios de armazenamento de glicogênio
Glycogen storage disorders are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. Type VI (Hers' disease). Type VII (Tarui's disease). Type IX (liver phosphorylase kinase deficiency). Type... About.

Patient information leaflet
Doença hepática gordurosa não alcoólica
Non-alcoholic fatty liver disease (NAFLD) describes a range of conditions caused by a build-up of fat within liver cells. It is very common and in many cases is linked to being obese or overweight. Much of the food we eat is broken down by the body into... This is what our bodies use for energy. Glucose can't be stored so it is turned into a.

Patient information leaflet
Nefropatia por IgA
Nefropatia por IgA is a condition in which a protein causes damage to the kidneys. The protein is called immunoglobulin A or IgA. Nephropathy means an illness that damages the kidney. The main job of the kidneys is to clear waste materials from the body and maintain a normal balance of fluids and chemicals in the body. The kidneys also have other.

Patient information leaflet
Doença renal diabética
Doença renal diabética é a complication that occurs in some people with diabetes. Treatment aims to prevent or delay the progression of the disease. Also, it aims to reduce the risk of developing cardiovascular diseases such as heart attack and stroke which are much more common than average in people with this disease. What is diabetic kidney.

Patient information leaflet
Doença de Wilson
Wilson's doença is a genetic disorder in which copper builds up in the body, mainly in the doença hepática and brain. Without any treatment, the build-up of copper can cause serious symptoms. Treatment is with medication to remove the excess copper and/or to prevent a further build-up of copper. What is Wilson's disease. Wilson's disease is a condition.

Patient information leaflet
Dieta na doença renal crônica
Chronic kidney disease (CKD) is a common long-term condition where the kidneys aren't working as well as they should be. There are some dietary choices that are recommended for people with early CKD. People with more advanced CKD may be advised to follow a special diet, usually with the support of a specialist dietician. It's important for.
Leitura adicional e referências
- Glycogen storage disease type VII; MedlinePlus, National Library of Medicine.
- Bruser A, Kirchberger J, Schoneberg T. Altered allosteric regulation of muscle 6-phosphofructokinase causes Tarui disease. Biochem Biophys Res Commun. 2012 Oct 12;427(1):133-7. doi: 10.1016/j.bbrc.2012.09.024. Epub 2012 Sep 17.
- Di Mauro S. Muscle glycogenoses: an overview. Acta Myol. 2007 Jul;26(1):35-41. No abstract available.
- Musumeci O, Bruno C, Mongini T, Rodolico C, Aguennouz M, Barca E, Amati A, Cassandrini D, Serlenga L, Vita G, Toscano A. Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord. 2012 Apr;22(4):325-30. doi: 10.1016/j.nmd.2011.10.022. Epub 2011 Nov 30.
- Toscano A, Musumeci O. Tarui disease and distal glycogenoses: clinical and genetic update. Acta Myol. 2007 Oct;26(2):105-7.
- Vives-Corrons JL, Koralkova P, Grau JM, Manu Pereira Mdel M, Van Wijk R. First description of phosphofructokinase deficiency in spain: identification of a novel homozygous missense mutation in the PFKM gene. Front Physiol. 2013 Dec 30;4:393. doi: 10.3389/fphys.2013.00393. eCollection 2013.
Compartilhe seus pensamentos ou experiências com outros em nosso comunidades de pacientes.
Inscreva-se no boletim informativo do Patient
Sua dose semanal de conselhos de saúde claros e confiáveis - escritos para ajudá-lo a se sentir informado, confiante e no controle.
Ao se inscrever, você aceita nossos Política de Privacidade. Você pode cancelar a inscrição a qualquer momento. Nunca vendemos seus dados.

